Revenue and Related Matters - Narrative (Details) - USD ($) $ in Millions |
3 Months Ended | ||
|---|---|---|---|
Mar. 31, 2026 |
Mar. 31, 2025 |
Dec. 31, 2025 |
|
| Transaction Price Allocated to Remaining Performance Obligations | |||
| Contract assets | $ 0.0 | $ 0.0 | |
| Revenue | 3.5 | $ 2.5 | |
| Amount of transaction price allocated to performance obligations | 18.0 | ||
| Akoya Biosciences, Inc. | |||
| Transaction Price Allocated to Remaining Performance Obligations | |||
| Revenue | 21.6 | ||
| Deferred revenue | 7.9 | ||
| Undelivered licenses of intellectual property | |||
| Transaction Price Allocated to Remaining Performance Obligations | |||
| Amount of transaction price allocated to performance obligations | 2.8 | ||
| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-04-01 | |||
| Transaction Price Allocated to Remaining Performance Obligations | |||
| Amount of transaction price allocated to performance obligations | $ 15.2 | ||
| Performance obligation satisfaction period | 12 months | ||